06.19.25 -- 3 Strategies For A Successful Journey Toward CGT Commercialization

The willingness to seek expert support from Rescue CROs when clinical trials face critical challenges is not a sign of weakness but a demonstration of accountability and commitment to excellence.

The 2025 American Academy of Dermatology (AAD) Annual Meeting underscored pivotal advancements in dermatology drug development, highlighting the essential role of innovative dermatology CROs.

It is vital to choose molecules for pharmaceutical development very carefully. How do drug developers know which strategy and approach is right for their molecule at an early stage?

Gain valuable insights into the role of sponsor-side Clinical Operations leadership, the risks of over-relying on CROs, and key strategies for fostering collaboration between sponsors and partners.

Learn how a bioanalytical testing partner with comprehensive solutions and unwavering commitment to quality can help you bring safe and effective drugs to market with confidence.

This full-service contract research organization has the expertise to get your early-phase clinical trial up and running safely and efficiently.

The global infectious disease clinical trial landscape has rapidly expanded between 2020 and 2024, driven by the urgency of emerging threats, technological innovation, and evolving regulatory frameworks.

This report outlines ten defining HEOR trends influencing global health decision-making.

Drawing from extensive experience in early-phase oncology, this guide offers a strategic framework for executing first-in-human (FIH) oncology trials with a patient-centric and risk-based approach.

Early integration of a target product profile (TPP) into early-stage planning is pivotal for steering drug development toward both regulatory success and commercial impact.

Discover how psiXchange streamlines the distribution, tracking, and acknowledgment of key safety documents, saving time, resources, and costs for global drug manufacturers and research organizations.